+359 886 516 705 office@healthpr.bg

You need a license to cut-and-paste this copyrighted news content.
Use this link to purchase your paid subscription ($200/year for individuals and $1,000/year for companies of every size): https://endpts.com/subscribe
Already a paid subscriber? Sign in to Endpoints News to remove this message.

The new cystic fibrosis triplet from Vertex ranks as the single most valuable late-stage therapy in the global pipeline, according to a new report from Vantage, the editorial arm of Evaluate. And they are way out ahead on the net present value scale used to rank these would-be blockbusters.

In this ranking, which you can see in full below, the Vertex triplet including VX-659 has a net present value — or NPV — of $14.4 billion as Phase III data loom, calculating costs and potential revenue.

by John Carroll

Read more here.